EGFR
Os inibidores do receptor do fator de crescimento epidérmico (EGFR) são compostos que bloqueiam a sinalização do EGFR, um receptor frequentemente superexpresso em vários tipos de câncer e que desempenha um papel crucial na angiogênese. Os inibidores de EGFR são usados para prevenir o crescimento e a metástase de tumores, interrompendo as vias que promovem a formação de vasos sanguíneos nos tumores. Esses inibidores são amplamente utilizados na pesquisa e terapia do câncer. Na CymitQuimica, oferecemos uma seleção diversificada de inibidores de EGFR de alta qualidade para apoiar sua pesquisa em oncologia e angiogênese.
Foram encontrados 595 produtos para "EGFR".
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Mutated EGFR-IN-1
CAS:Mutated EGFR-IN-1 (Osimertinib analog) is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activatingFórmula:C25H31N7OPureza:98.91%Cor e Forma:White SolidPeso molecular:445.56Barecetamab
CAS:Barecetamab (ISU-104) is a humanized monoclonal antibody against tyrosine protein kinase ErbB3 with anticancer activity.Pureza:97.1% (SDS-PAGE); 96.4% (SEC-HPLC) - 97.1% (SDS-PAGE); 96.4% (SEC-HPLC)Cor e Forma:Transparent LiquidPeso molecular:143.86 kDaGancotamab
CAS:Gancotamab (MM-302) is a polyethylene glycolated liposome targeting HER2 with antitumor activity for the study of advanced HER2-positive breast cancer.Pureza:96.7% (SDS-PAGE); 98.4% (SEC-HPLC) - 96.7% (SDS-PAGE); 98.4% (SEC-HPLC)Cor e Forma:Transparent LiquidPeso molecular:25.79 kDaIntetumumab
CAS:Intetumumab (CNTO 95) is a fully humanized anti-α(v)-integrin monoclonal antibody that is a radiosensitizer for xenograft tumor-bearing mice.Pureza:97.6% (SDS-PAGE); 97.1% (SEC-HPLC) - 97.6% (SDS-PAGE); 97.1% (SEC-HPLC)Cor e Forma:Transparent LiquidPeso molecular:145.56 kDaLapatinib Ditosylate
CAS:Lapatinib Ditosylate (Tykerb ditosylate) is an effective EGFR and ErbB2 inhibitor (IC50: 10.8/9.2 nM for EGFR/ErbB2).Fórmula:C29H26ClFN4O4S·2C7H8O3SPureza:99.41%Cor e Forma:White SolidPeso molecular:925.46Mevastatin
CAS:Mevastatin (ML236B) is an HMG-CoA reductase inhibitor that was initially isolated from the mold Pythium ultimum.Fórmula:C23H34O5Pureza:99.12%Cor e Forma:SolidPeso molecular:390.51LCH-7749944
CAS:LCH-7749944 suppresses human gastric cancer cell growth, induces apoptosis, and inhibits PAK4 with IC50 of 14.93 μM.Fórmula:C20H22N4O2Pureza:99.48%Cor e Forma:SolidPeso molecular:350.41Gefitinib
CAS:Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations.Fórmula:C22H24ClFN4O3Pureza:99.92% - >99.99%Cor e Forma:White SolidPeso molecular:446.90AV-412
CAS:AV-412 (MP412) is an EGFR inhibitor (EGFR, EGFR T790M, EGFR L858R, EGFR L858R/T790M and ErbB2 with IC50s of 0.75, 0.79, 0.5, 2.3, 19 nM).Fórmula:C41H44ClFN6O7S2Pureza:99.85% - 99.92%Cor e Forma:SolidPeso molecular:851.41Ref: TM-T10419
1mg42,00€2mg55,00€5mg90,00€1mL*10mM (DMSO)129,00€10mg137,00€25mg240,00€50mg403,00€100mg582,00€Losatuxizumab
CAS:Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody with potential anti-tumor activity for the study of advanced malignant solid tumors.Pureza:97.3% (SDS-PAGE); 95.1% (SEC-HPLC) - 97.3% (SDS-PAGE); 95.1% (SEC-HPLC)Cor e Forma:Transparent LiquidPeso molecular:144.85 kDaPropanedinitrile,2-[(4-methoxyphenyl)methylene]-
CAS:Fórmula:C11H8N2OPureza:98%Cor e Forma:SolidPeso molecular:184.1940Panitumumab
CAS:Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).Pureza:95% - 98.1% (SDS-PAGE); 99.4% (SEC-HPLC)Cor e Forma:Transparent LiquidPeso molecular:144.31 kDaG7-18NATE
CAS:G7-18NATE, a peptide inhibitor of Grb7, exhibits micromolar affinity (K D = 18.1 μM) for binding to the Grb7-SH2 domain. It effectively inhibits cell proliferation, motility, invasion, and 3D culture formation in various cancer cell lines [1] [2].Fórmula:C67H80N14O19SCor e Forma:SolidPeso molecular:1417.5EGFR/PI3Kα-IN-1
EGFR/PI3Kα-IN-1 (compound 30k), a dual EGFR/PI3Kα inhibitor, exhibits potent activity with IC 50 values of 3.6 nM (EGFRL858R/T790M) and 30 nM (PI3Kα). It effectively inhibits tumor cell proliferation and demonstrates significant anticancer activity.Fórmula:C50H49N11O5SCor e Forma:SolidPeso molecular:916.06JBJ-09-063 TFA
JBJ-09-063 TFA, an EGFR inhibitor selective for EGFR mutations, IC50s: 0.147-0.396 nM, blocks EGFR/Akt/ERK signaling, for EGFR-mutant lung cancer research.Fórmula:C33H30F4N4O5SCor e Forma:SolidPeso molecular:670.67SJF 1521
CAS:SJF 1521 is an EGFR degrader belonging to the PROTAC class that selectively degrades EGFR while preserving HER2.Fórmula:C57H61ClFN7O9SPureza:99.20%Cor e Forma:SolidPeso molecular:1074.65DS06652923
DS06652923 is an orally active inhibitor targeting EGFR triple mutations. It exhibits growth-inhibitory effects on Ba/F3EGFRdel19/T90M/C795S cells, with a GI50 value of 9.4 nM. Additionally, DS06652923 induces tumor regression in the Ba/F3 syngeneic transplantation model.Cor e Forma:Odour SolidEGFR-IN-76
CAS:EGFR-IN-76 is a potent EGFR inhibitor.Fórmula:C30H30ClFN6O2Pureza:97.02% - 97.72%Cor e Forma:SolidPeso molecular:561.05OK2
OK2, a specific inhibitor of the CCN2/EGFR interaction, effectively disrupts this interaction by binding to the CT domain of CCN2.Fórmula:C42H62N14O9Pureza:98%Cor e Forma:SolidPeso molecular:907.03Lumretuzumab
CAS:Lumretuzumab (RG-7116) is a humanized anti-HER3 monoclonal antibody with antitumor activity.Pureza:95.3% (SDS-PAGE); 96.4% (SEC-HPLC) - 95.3% (SDS-PAGE); 96.4% (SEC-HPLC)Cor e Forma:Transparent LiquidPeso molecular:146.9 kDaMM-151
CAS:MM-151 is a humanized IgG1 monoclonal antibody targeting EGFR. It binds to multiple regions of the EGFR extracellular domain (ECD) and decreases mutations in circulating free tumor DNA associated with EGFR resistance. MM-151 significantly inhibits EGFR signaling and cell growth and is applicable in research on resistant cancers such as colorectal cancer, non-small cell lung cancer, and triple-negative breast cancer.Cor e Forma:LiquidMS9427
CAS:MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.Fórmula:C48H58ClFN8O12Cor e Forma:SolidPeso molecular:993.47HER2-IN-14
CAS:HER2-IN-14 (Compound 34) is a potent inhibitor of HER2, achieving an inhibitory concentration (IC50) of 18 nM.Fórmula:C26H23ClF2N8O3Cor e Forma:SolidPeso molecular:568.96EP26
EP26 is an orally active and potent inhibitor of EGFR and PD-L1, with IC50 values of 48.6 nM and 1.77 µM, respectively. It reduces the protein expression of p-EGFR and induces cell cycle arrest at the G0/G1 phase. EP26 shows potential for glioblastoma research.Fórmula:C42H42ClFN4O5Cor e Forma:SolidPeso molecular:736.28278EGFR-IN-118
EGFR-IN-118 (Compound 4a) is an inhibitor of the tyrosine kinase EGFR. It exhibits anticancer properties, effectively inhibiting the proliferation of MCF-7 and PC3 cells, with IC50 values of 2.53 and 3.25 µg/ml, respectively. Additionally, EGFR-IN-118 demonstrates antioxidant activity by inhibiting DPPH free radicals, with an IC50 of 10.04 µg/ml.Fórmula:C26H23N3O2SCor e Forma:SolidPeso molecular:441.1511EGFR-TK-IN-2
EGFR-TK-IN-2 (compound 10b) is an EGFR-TK inhibitor with an IC50 value of 0.16 μM, and it suppresses cell proliferation.Fórmula:C22H19N3O3Cor e Forma:SolidPeso molecular:373.14264HLX-22
CAS:HLX-22 is a humanized monoclonal antibody targeting HER2. When used in combination with trastuzumab, HLX-22 can induce apoptosis in HER2-overexpressing breast and gastric cancer cells. It also exhibits potent antitumor activity against advanced solid tumors.AZ14133346
AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR exon 20 insertion, with an IC50 of 85 nM. It plays a significant role in cancer research.Fórmula:C29H27N5O2Cor e Forma:SolidPeso molecular:477.21648Varlitinib
CAS:Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively.Fórmula:C22H19ClN6O2SPureza:99.7%Cor e Forma:SolidPeso molecular:466.94MC-Val-Cit-PAB-Amide-TLR7 agonist 4
CAS:MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate is a conjugate formed by linking MC-Val-Cit-PAB-Amide and TLR7 agonist 4, useful for cancer research.Fórmula:C52H72N12O11Pureza:97.70%Cor e Forma:White SolidPeso molecular:1041.2HER2-IN-13
CAS:HER2-IN-13 (Compound 33) serves as an effective HER2 inhibitor, exhibiting an IC50 value of 8 nM, and additionally demonstrates inhibition of wt-EGFR with anFórmula:C26H23ClF2N8O3Cor e Forma:SolidPeso molecular:568.96Gefitinib N-oxide hydrochloride
Gefitinib N-oxide hydrochloride is an N-oxide of EGFR inhibitor Gefitinib with IC50 of 2-37 nM.Fórmula:C22H24ClFN4O41·5HClCor e Forma:SolidPeso molecular:517.59EGFR-IN-42
EGFR-IN-42 (17b) is a potent EGFR inhibitor with nanomolar efficacy, merging tamoxifen/endoxifen and gefitinib, exhibiting enhanced anti-cancer action.Fórmula:C49H53ClFN5O5Cor e Forma:SolidPeso molecular:846.43EGFR-IN-43
EGFR-IN-43 (17c) is a potent EGFR inhibitor with ER antagonist action, tamoxifen/endoxifen+gefitinib linkage, and strong anticancer activity.Fórmula:C50H55ClFN5O5Cor e Forma:SolidPeso molecular:860.45EGFR-TK-IN-5
EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.Fórmula:C26H20ClFN4OSCor e Forma:SolidPeso molecular:490.98EGFR-IN-22
CAS:EGFR-IN-22: potent for EGFR (IC50: 4.91 nM) & L858R/T790M/C797S mutation (IC50: 0.54 nM).Fórmula:C38H47BrFN10O2PCor e Forma:SolidPeso molecular:805.72Inetetamab
Inetetamab is a recombinant humanized antibody targeting HER2 receptor domain IV, with anticancer activity, inducing pyroptosis in lung adenocarcinoma.Pureza:96.54% (SEC-HPLC) - 96.54% (SEC-HPLC)Cor e Forma:LiquidPeso molecular:145.1 kDaEGFR-IN-15
CAS:EGFR-IN-15 (compound I-005) is a potent EGFR inhibitor, exhibiting an IC50 value of 4 nM. This compound holds potential for oncological research applications.Fórmula:C24H25BrN6O2Cor e Forma:SolidPeso molecular:509.408BMS-599626
CAS:BMS-599626 (AC480) has been used in trials studying the treatment of Cancer, Metastases, and HER2 or EGFR Expressing Advanced Solid Malignancies.Fórmula:C27H27FN8O3Pureza:98.73%Cor e Forma:SolidPeso molecular:530.55EGFR kinase inhibitor 2
EGFR kinase inhibitor 2 (compound A-7) is a potent EGFR inhibitor targeting the mutations EGFRL858R/T790M/C797S and EGFRDel19/T790M/C797S. This compound shows potential in addressing acquired resistance in the treatment of non-small cell lung cancer.Fórmula:C39H40N6O5Cor e Forma:SolidPeso molecular:672.30602EGFR-IN-140
EGFR-IN-140 (Compound 31) is an inhibitor of EGFR, effectively targeting both wild-type EGFR and the EGFRL858R/T790M/C797S mutant, with Ki values of 0.95 nM and 2.1 nM, respectively. Additionally, it inhibits EGFRdel19/T790M/C797S in Ba/F3 cells with an IC50 of 56.9 nM and demonstrates antitumor activity in mouse models.Fórmula:C27H37FN8O2Cor e Forma:SolidPeso molecular:524.633EGFR-IN-127
EGFR-IN-127 is an ATP-competitive inhibitor targeting EGFR, with IC50 values of 136.3 nM for EGFRdel19 and 161.2 nM for EGFRdel19/T790M/C797S. This compound holds potential for the study of non-small cell lung cancer (NSCLC).Cor e Forma:Odour SolidMatuzumab
CAS:Matuzumab (EMD 72000) is a humanized monoclonal antibody targeting EGFR that can be used to study non-small cell lung cancer.Pureza:95%Cor e Forma:LiquidPeso molecular:145.9 kDaEGFR-IN-124
EGFR-IN-124 (compound 10A) is an EGFR inhibitor with an IC50 value of 0.54 μM, utilized in cancer research.Cor e Forma:Odour SolidJAK 3 inhibitor IV
CAS:JAK 3 inhibitor IV (ZM 39923 hydrochloride) is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found toFórmula:C16H19NOPureza:98%Cor e Forma:SolidPeso molecular:241.33DP-C-4
DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1].Cor e Forma:SolidAZ14240475
AZ14240475 is a potent, selective, brain-penetrant inhibitor of EGFREx20Ins mutants (EGFREx20Ins mutants) with a pIC50 of 7.6, playing a significant role in cancer research.Fórmula:C23H15ClF2N6O2Cor e Forma:SolidPeso molecular:480.854Depatuxizumab MMAF
Depatuxizumab-MMAF, an antibody-drug conjugate (ADC), comprises an EGFR-targeted antibody linked to McMMAF and is utilized in glioblastoma research.Cor e Forma:LiquidPeso molecular:148.24 kDaEGFR-IN-7
CAS:EGFR-IN-7 (TQB3804) is a selective and potent EGFR kinase inhibitor.Fórmula:C32H41BrN9O2PPureza:98.2% - 99.49%Cor e Forma:White SolidPeso molecular:694.6Ref: TM-T11161
10mgA consultar25mgA consultar50mgA consultar100mgA consultar500mgA consultar1mg92,00€5mg219,00€
![Propanedinitrile,2-[(4-methoxyphenyl)methylene]-](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb-webp%2FDA007L0Q.webp&w=3840&q=75)
